

**Book early
and
save up to £720**
See registration page
for details

ALSO
**Exclusive discounts
for early stage
biotechs**

worldvaccine

CONGRESS 2009

5 - 8 October 2009, Palais de Congrès de Lyon, Lyon, France

Hear from:



Dr Ole Olesen
Scientific Officer, Neglected
Infectious Diseases,
Infectious Diseases Unit,
DG-Research
European Commission



Dr Pierluigi Lopalco
Senior Expert,
Scientific Advice Unit
European Centre for
Disease Prevention and
Control



Didier Hoch
President,
sanofi pasteur MSD
and Former President,
European Vaccine
Manufacturers



Dr Philippe Dro
Chief Executive Officer
GlycoVaxyn



Dr Matthias Schroff
Chief Executive Officer
Mologen

Produced by:

terrapiinn
use your brain

World health



Innovation and opportunity for pharma, biotechs, healthcare and investors

Representation from key European Commission and regulatory agencies

DG Research, DG SANCO, ECDC, EDQM, CHMP, VWP, MHRA, PEI, FAMHP and MEB provide vision and clarity on future industry progress and opportunities

Europe's largest commercial vaccine industry congress for decision makers across European and North America regions

Including World class multiple speaker representation from Baxter, GSK Biologicals, MedImmune, Novartis Vaccines and Diagnostics, Pfizer, sanofi pasteur, sanofi pasteur MSD, Solvay and Wyeth Vaccines

Critical market opportunities outlined in billion Euro vaccine market

European policy frameworks, vaccine regulation and authorisation, vaccine R&D innovation and introduction, Influenza market sustainability, corporate growth strategies and funding sources

1-2-1 partnering opportunities with "Contact"

Schedule dedicated onsite meetings
with partners and gain the visibility your
company needs.

Speaker line-up	page 2
Partnering opportunities	page 3
Conference programme	page 3-6
Sponsorship opportunities	page 7
All booking offers and options	page 8

www.lifescienceworld.com/2009/wvcl

Sponsors:



imagination at work



Europe's largest and most influential vaccine congress

Vaccines: a market and industry on the rise

These are electrifying times for the European vaccine industry. With the European market for **vaccines set to grow to an unprecedented Euro 4.97 billion** by 2012, it represents a compound annual growth rate of 10.8 per cent over the next 3 years. With similar predictions for the pharmaceutical industry unlikely during the same period, the vaccine market continues to remain a very prosperous field.

While the number of diseases covered by vaccines available in Europe have not increased significantly in the past few years, the introduction and development of novel and improved products, especially for new diseases such as HPV, rotavirus, pneumococcal and meningococcal, are driving the overall market.

With the major players aiming their vaccine development programmes at the adolescent and adult groups, it is a strategy that is likely to be followed by the majority of vaccine manufacturers in Europe for the long term. Furthermore, enterprises in Western European countries continue to focus more and more on establishing greater diversity in therapeutic and preventive vaccine pipelines, a development that will likely continue to stimulate the region's vaccine market.

Hear from the World's leading business leaders and vaccine stakeholders

The **11th annual World Vaccine Congress Lyon** is Europe's largest event addressing the research and development and commercial manufacture of vaccines across the therapeutic and prophylactic landscape. Featuring **the most influential and innovative industry and business leaders** from European agencies, global big pharma and biotechs, this lively and energetic meeting combines **experts keynotes, cutting-edge case studies** and **dedicated 1-2-1 networking in a deal-making** environment where debate is encouraged and discussion thrives.



A fully interactive conference experience

The congress covers the advancing markets of therapeutic and prophylactic candidates against a target demographic of pediatric, adolescent and adult recipients. With an increased and highly significant level of involvement from big pharma this year, participant companies in the 2009 speaker faculty include **Baxter, GSK Biologicals, MedImmune, Novartis Vaccines and Diagnostics, Pfizer, sanofi pasteur, sanofi pasteur MSD, Solvay and Wyeth Vaccines**, plus presence from **Intercell** and **Crucell**.

Capitalise on the resurgence of an industry continuing to write new success stories every day, and attend the region's number one event for major vaccine players and their respective senior level representatives. Officially the longest-running and largest vaccine event in Europe, **World Vaccine Congress Lyon** continues to deliver a forum where you meet more of the World's most compelling and influential scientific and strategic leaders, facilitating education, debate and business.

World class industry stakeholders leading the 2009 speaker faculty



Dr Ole Olesen
Scientific Officer, Neglected Infectious Diseases, Infectious Diseases Unit, DG-Research
European Commission



Dr Allan Jarvis
Senior Vice President, Corporate Development
sanofi pasteur



Dr Frederic Lehmann
Director, Clinical Research and Development
GSK Biologicals



Dr Pierluigi Lopalco
Senior Expert, Scientific Advice Unit
European Centre for Disease Prevention and Control



Dr Beatrice de Vos
Vice President, Global Scientific and Medical Affairs
sanofi pasteur



Dr Nathalie Garçon
Vice President, Head of Research and North America R&D
GSK Biologicals



Didier Hoch
President,
sanofi pasteur MSD
and Former President,
European Vaccine Manufacturers



Dr Patrick Caubel
Vice President, Head Global Pharmacovigilance
sanofi pasteur



Dr Jeffrey Ulmer
Global Head of External Research
Novartis Vaccines and Diagnostics



Dr Luc Hessel
Executive Director, Medical and Public Affairs, Europe
sanofi pasteur MSD



Dr Joe Cohen
Vice President R&D, Head of Vaccines for Emerging Diseases and HIV
GSK Biologicals



Dr Peter Dull
Head of Department, Meningococcal Conjugate Vaccines
Novartis Vaccines & Diagnostics



Extensive 1-2-1 partnering opportunities – contact, connect, collaborate

Europe's premier vaccine congress, *World Vaccine Congress Lyon*, brings together decision-makers from leading vaccine pharmaceutical, biotechnology and contract service companies from around the world for 4 days of focused networking, presentations, expert panels and 1-2-1 partnering.

No other vaccine industry event this year matches the exclusive access to the industry's major players that *World Vaccine Congress Lyon* offers. Providing you with more mediums to facilitate the all important business negotiations, and with over 15 hours of dedicated face-to-face time with your peers and prospective clients, we will help you strengthen your corporate identity and visibility.

contact – your unique online partnering tool

Introducing you to your peers and your suppliers. 'Contact' is Terrapinn's unique online introductory service. Don't leave meeting the best event attendees to chance. Identify your clients, contact them before the event, engage onsite and follow through after the event. Stay in contact!



– meet 120 attendees in just 60 mins

Speed networking: designed to quickly introduce you to a large number of vaccine decision makers in one powerful 60 minute session, these meetings initiate contacts that often last well beyond the four days of the conference and blossom into fruitful and lasting business.



– maximise your networking opportunities

To celebrate this year's *World Vaccine Congress Lyon* we will be hosting a Gala Dinner at the renowned Brasserie Georges following the conference programme on the 6th October, a monument of Lyonnaise gastronomy since 1836, the oldest in Lyon.

Key include:

Dr Hartmut Ehrlich
Vice President, Global
Research and Development
Baxter BioScience



Dr Katherine Cohen
Vice President, Corporate
and Business Development,
Intercell

Dr Otfried Kistner
Senior Director Virology /
Viral Vaccines
Baxter BioScience



Dr Philippe Dro
Chief Executive Officer
GlycoVaxyn

Dr Jeff Southerton
Executive Director,
Worldwide Business
Development
Pfizer Global R&D



Dr Matthias Schroff
Chief Executive Officer
Mologen

Dr Bram Palache
Global Scientific
Communication and Public
Affairs Director for Influenza
Vaccines
Solvay Biologicals



Christian Rochet
Chief Executive Officer
Mymetics

Vaccine Regulatory Framework Day Monday 5 October 2009

EUROPEAN FRAMEWORKS FOR VACCINATION POLICY

- 08.30 Registration and morning coffee**
- 09.30 Chairman's opening remarks**
- 09.40 Keynote address: how is the environment for European vaccine research and development stimulating industry?**
Dr Ole Olesen, Scientific Officer, Neglected Infectious Diseases, Infectious Diseases Unit, DG-Research, European Commission
- 10.10 Identifying DG SANCO initiatives: enhancing industry cooperation on the introduction of new vaccines**
Antoon Gijssens, Policy Officer, Unit C3 - Health Threats, Directorate C, Public Health and Risk Assessment, Directorate-General Health and Consumer Protection, DG SANCO C3, European Commission
- 10.40 What contribution is the European Centre for Disease Control and Prevention making in co-operating on vaccination policy?**
Dr Pierluigi Lopalco, Senior Expert, Scientific Advice Unit, European Centre for Disease Prevention and Control
- 11.10 Panel session: what implication do future vaccine plans, frameworks and initiatives have on industry?**
Dr Ole Olesen, Scientific Officer, Neglected Infectious Diseases, Infectious Diseases Unit, DG-Research, European Commission
Antoon Gijssens, Policy Officer, Unit C3 - Health Threats, Directorate C, Public Health and Risk Assessment, Directorate-General Health and Consumer Protection, DG SANCO C3, European Commission
Dr Pierluigi Lopalco, Senior Expert, Scientific Advice Unit, European Centre for Disease Prevention and Control
- 11.40 Morning coffee**

EUROPEAN VACCINE EVALUATION AND AUTHORISATION

- 12.10 How are emerging vaccine therapies authorised under evolving European centralised authorisation procedures?**
Representative to be confirmed, **EMA**
- 12.40 How are vaccine authorisations influenced by the EDQM and European Pharmacopoeia?**
Dr Jean-Marc Spieser, Director, Biological Standardisation Department, **EDQM, Council of Europe**
- 13.10 Networking lunch**
- 14.30 Overcoming decentralised national challenges to resolve vaccine authorisation and assessment**
Dr Hans van Gompel, Senior Regulatory Project Leader, Medicines Evaluation Board, The Netherlands
- 15.00 Identifying ongoing VWP initiatives and facilitating ongoing marketing authorisation applications**
Dr Pieter Neels, FAMHP, Belgium and Co-Chair, Vaccine Working Party, **CHMP**
- 15.30 Afternoon tea**
- 16.00 Panel session: what are key European Member State approaches to vaccination authorisation?**
Dr Mair Powell, Medical Assessor, Licensing Division, **MHRA**
Dr Volker Öppling, Head of Section, Microbial Vaccines, **PEI**
Dr Pieter Neels, FAMHP, Belgium and Co-Chair, Vaccine Working Party, **CHMP**
- 16.40 What role can European vaccine manufacturers play in facilitating vaccination policy?**
Didier Hoch, President, **sanofi pasteur MSD** and Former President, **EVM**
- 17.10 Close of congress day followed by networking drinks**



Congress Day 1 Tuesday 6 October 2009

AN EVOLVING ROLE FOR BIG PHARMA

- 09.00** Chairman's opening remarks
- 09.10** Vaccine sector growth: are innovative investing models the answer to addressing vaccine market demand
Dr Eric Le Berrigaud, Equity Analyst – Pharmaceutical, Raymond James Euro Equities
- 09.40** How to overcome existing challenges for vaccine manufacturers driving growth through innovation
Didier Hoch, President, **sanofi pasteur** MSD and Former President, **EVM**

VACCINE CORPORATE GROWTH STRATEGIES

- 10.10** Cross border strategic growth and acquisition strategies
Dr Jeff Southerton, Executive Director, Worldwide Business Development, **Pfizer Global R&D**
- 10.40** Morning coffee

- 11.10** Innovative acquisitions and the key to success for pharma and biotech models: **sanofi pasteur** and **Acambis**
Dr Allan Jarvis, SVP, Corporate Development, **sanofi pasteur**
- 11.40** How biotechs can consolidate growth during times of market consolidation: the **Intercell / IOMAI** perspective
Dr Katherine Cohen, VP, Corporate and Business Development, **Intercell**
- 12.10** Panel session: where are Big Pharma and biotech focusing and pursuing corporate development opportunities?
Dr Jeff Southerton, Executive Director, Worldwide Business Development, **Pfizer Global R&D**
Dr Allan Jarvis, SVP, Corporate Development, **sanofi pasteur**
Dr Jeffrey Ulmer, Global Head of External Research, **Novartis Vaccines and Diagnostics**
Dr Katherine Cohen, VP, Corporate and Business Development, **Intercell**
- 12.50** Networking lunch

STREAM 1

BIOTECH START-UP INNOVATION SHOWCASES

- 13.50** A novel type of live vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist
Dr Thomas Muster, Chief Executive Officer, **AVIR Green Hills Biotechnology**
- 14.05** Novel infectious disease and **Campylobacter** vaccines
Dr Ingelise Saunders, Chief Executive Officer, **ACE Biosciences**
- 14.20** Fostering clinical development for HIV Vaccines
Dr Kalevi Reijonen, Chief Executive Officer, **FIT Biotech**
- 14.35** Pre-clinical prostate- and B-cell lymphoma cancer vaccines
Dr Ole Henrik Brekke, Chief Executive Officer, **Vaccibody**
- 14.50** Establishing novel Meningitis B vaccine development
Dr Graham Clarke, Chief Executive Officer, **ImmBio Ltd.**
- 15.05** Biotech Innovation showcase Q&A session
- 15.30**  meet 120 attendees in just 60 mins
- 16.30** Afternoon tea

VACCINE INTRODUCTION REVIEW

- 17.00** Current needs of benefit and risk management post-marketing for recently introduced vaccines
Dr Guy Demol, Executive Director, Medical & Scientific Affairs, **sanofi pasteur** MSD and Chair, Risk Management and Pharmacovigilance Working Group, **EVM**
- 17.30** Evolution of Meningococcal conjugate **ACYW135**
Dr Peter Dull, Head of Department, Meningococcal Conjugate Vaccines, **Novartis Vaccines & Diagnostics**
- 18.00** Clinical updates for investigational 13-valent **PVC**
Dr Susan Tansey, Director, Clinical Research, **Wyeth Vaccines**

OR

STREAM 2

EUROPEAN INFLUENZA PREPAREDNESS

- 13.50** Intradermal (ID) microinjection flu vaccine development
Dr Beatrice de Vos, Vice President, Global Scientific and Medical Affairs, **sanofi pasteur**
- 14.20** Cell culture derived pandemic Influenza vaccines
Dr Hartmut Ehrlich, Vice President, Global Research and Development, **Baxter BioScience**
- 14.50** Universal Influenza-A vaccine development and synthetic vaccines for mutating viruses
Carlton Brown, Chief Executive Officer, **Immune Targeting Systems**
- 15.10** Enhancing intranasal influenza vaccine development with **Mimopath™** technology
Dr Kees Leenhouts, Chief Scientific Officer, **Mucosis**
- 15.30**  meet 120 attendees in just 60 mins
- 16.30** Afternoon tea

THE FLU PARADOX

- 17.00** Strategies to improve seasonal vaccination and pandemic preparedness coverage of seasonal influenza
Dr Franz Karcher, Legislative Officer, DG SANCO C3, European Commission
- 17.30** Sustainability into the European Influenza vaccine market
Dr Bram Palache, Global Scientific Communication and Public Affairs Director for Influenza Vaccines, **Solvay Biologicals** and Co-Chair, Influenza Working Group, **EVM**
- 18.00** Extending vaccination development and supply to reap the benefits of immunisation
Dr Luc Hessel, Executive Director, Medical and Public Affairs, Europe, **sanofi pasteur** MSD and Chair, Public Health Policy and Advocacy Working Group, **EVM**

18.30 Close of congress day followed by  at Brasserie Georges

Congress Day 2 Wednesday 7 October 2009

STREAM 1

OR

STREAM 2

09.00 Chairman's opening remarks

THE FUTURE DIRECTION OF VACCINE R&D

09.10 Innovation and market access: promoting rapid access to innovative vaccines in the EU
Dr Rudi Daems, Director, Policy & Partnerships, **GSK Biologicals**

09.40 How is clinical development progressing for Neisseria Meningitidis B vaccine development?
Dr Peter Dull, Head of Department, Meningococcal Conjugate Vaccines, **Novartis Vaccines & Diagnostics**

10.10 Innovative approaches to RSV vaccine development and VLP based vaccines
Dr Rahul Singhvi, Chief Executive Officer, **Novavax**

10.40 Morning coffee

11.20 Novel vaccine technology against staphylococcus aureus
Dr Raafat Fahim, Chief Executive Officer, **Nabi Biopharmaceuticals**

11.50 Assessing clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma
Dr Frederic Lehmann, Director, Clinical Research and Development, **GSK Biologicals**

12.20 How are hepatitis B vaccine candidates demonstrating the potential to provide increased protection?
Dr Melissa Malhame, Project Leader HEPLISAV, **Dynavax Technologies**

12.50 Networking lunch

14.10 Pursuing in parallel Immunodrug™ programs addressing important chronic disease indications
Dr Martin Bachmann, Chief Scientific Officer, **Cytos Biotechnology**

14.40 What targets are advancing TB vaccine development?
Dr Leander Grode, Project Manager and Director, Business Development, **Vakzine Projekt Management**

15.10 Identifying promising and novel approaches to Malaria vaccine studies
Dr Odile Leroy, Director of Clinical and Regulatory Affairs, **Statens Serum Institut** and Executive Director, **European Malaria Vaccine Initiative**

15.40 Afternoon tea

16.10 Key industry investigations HIV vaccine development
Dr Joe Cohen, Vice President R&D, Head of Vaccines for Emerging Diseases and HIV, **GSK Biologicals**

16.40 Making headway on Shigella vaccine R&D
Dr Armelle Phalipon, Director, Molecular Microbial Pathogenesis Unit, **Institut Pasteur**

17.10 Viable candidate development for Dengue Fever vaccine
Dr Dan Stinchcomb, Chief Executive Officer, **Inviragen**

09.00 Chairman's opening remarks

VACCINE CLINICAL DEVELOPMENT COMPLEXITIES

09.10 Specificities of developing a novel influenza vaccine with unusual preclinical / clinical investigations
Dr Martine Denis, Senior Director, Clinical Development, Influenza Vaccines, **sanofi pasteur**

09.40 Interpreting Clinical safety and effectiveness of adjuvanted vaccines
Dr Angelika Banzhoff, Head European Pharmacovigilance, Clinical Trial Safety and Risk Assessment, EU/EEA QPPV, **Novartis Vaccines and Diagnostics**

10.10 Rational design and standardised evaluation of novel genetic vaccines: avenues to systems biology
Dr David Klatzmann, Professor of Immunology, **UPMC**

10.40 Morning coffee

MANUFACTURE, PROCESS DEVELOPMENT AND SCALE-UP

11.20 Critical process parameters to maximise vaccine yield and quality
Dr Catarina Flyborg, Leader Vaccine Initiatives, **GE Healthcare Life Sciences**

11.50 Transition to bioprocess and new generation
Dr Vittoria Pellegrini, Head, Technical and Business Affairs, **Novartis Vaccines & Diagnostics**

12.20 New technologies for flexible vaccine production
Robert Shaw, Director, Strategic Marketing and WW Training Program Director, Vaccines and Emerging Biotech, **Millipore**

12.50 Networking lunch

14.10 A benchmark for economic vaccine scale-up strategies
Dr Simon Hsu, Principal Scientist, Vaccine Process Biochemistry, **MedImmune**

14.40 End-to-end process development and scaleable manufacture
Dr Phil Ball, Technical Director, USA, **Eden Biodesign**

15.10 Mechanisms for vaccine production supply into the EU
Dr Tarit Mukhopadhyay, Lecturer, Vaccine Bioprocess Development, **University College London**

15.40 Afternoon tea

CELL CULTURE BASED PRODUCTION - THE NEXT FRONTIER?

16.10 Cell-culture derived vaccine technology advances
Dr Otfried Kistner, Senior Director Virology / Viral Vaccines, **Baxter BioScience**

16.40 How to advance manufacturing using scalable solutions
Jim Robinson, Vice President, Technical Operations and Quality Operations, **Novavax**

17.10 Scalable manufacture for virus and recombinant proteins
Dr Stephen Brown, Director of Manufacturing, **Vivalis**

17.40 Close of congress day followed by networking drinks



Congress Day 3 Thursday 8 October 2009

STREAM 1

09.00 Chairman's opening remarks

STREAMLINING VACCINE ADJUVANT R&D

09.10 European approaches: current non-clinical testing requirements for adjuvants / adjuvanted vaccines
Dr Jan Willem van der Laan, Senior Assessor
 Pharmaceuticals, RIVM

09.40 Clinical experience and key steps leading to AS-adjuvanted vaccine registration
Dr Nathalie Garçon, VP, Head of Research and North America R&D, **GSK Biologicals**

10.10 How to establish a mechanism of action of TLR-dependent and independent adjuvants
Dr Ennio de Gregorio, Head of Immunology, **Novartis Vaccines & Diagnostics**

10.40 Morning coffee

11.10 Outlining novel cellular adjuvant products for therapeutic vaccines against cancer
Dr Vincent Serra, Chief Executive Officer, **Wittcell**

INTRA-MARKET REGULATORY CHALLENGES

11.40 Examining global regulatory frameworks for novel vaccine introduction into regional markets
Stéphane Callewaert, Manager, Worldwide Vaccine Registration Management, **GSK Biologicals**

12.10 Panel session: how can you align strategies with regulation to avoid barriers to vaccine development?
Mary Allin, Senior Director, Regulatory Affairs, **Wyeth Research**
Eddie Reilly, Head, Regulatory Affairs Europe and International, **Novartis Vaccines and Diagnostics**
Stéphane Callewaert, Manager, Worldwide Vaccine Registration Management, **GSK Biologicals**
Dr Hanna Nohynek, Senior Vaccine Consultant, **Encorium**

13.00 Networking lunch

VACCINE SAFETY EVALUATION

14.00 Exploiting industry procedures and strategies to enhance risk-benefit assessments and safety reporting
Dr Patrick Caubel, VP, Head Global Pharmacovigilance, **sanofi pasteur**

14.30 How to ensure structured post-marketing safety data and pharmacovigilance planning
Dr Thomas Verstraeten, VP, Head, Biologicals Clinical Safety and Pharmacovigilance **GSK Biologicals**

15.00 From post-marketing surveillance to risk management
Dr Katharina Hartmann, Head of Pharmacovigilance, **Crucell**

15.30 Panel session: how can industry respond to unexpected quality and safety issues arising at late stages?
Dr Patrick Caubel, VP, Head Global Pharmacovigilance, **sanofi pasteur**
Dr Thomas Verstraeten, VP, Head, Biologicals Clinical Safety and Pharmacovigilance **GSK Biologicals**
Dr Katharina Hartmann, Head of Pharmacovigilance, **Crucell**

16.00 Close of congress followed by afternoon tea.

OR

STREAM 2

09.00 Chairman's opening remarks

CONFRONTING ECONOMIC FUNDING CHALLENGE

09.10 What's driving current and future investment interest in vaccines and where will it lead?
Dr Andrew Baum, Managing Director, Head of European Healthcare, **Morgan Stanley**

09.40 What innovative approaches are open to your company in attracting and securing new funding?
Gilles Nobecourt, Investment Director, **Edmond de Rothschild Investment Partners**

10.10 Identifying non-dilutive funding sources to complete your core developmental phases
Dr Cornelius Schmaltz, Scientific Officer, Infectious Diseases Unit, Health Directorate, DG Research, **European Commission**

10.40 Morning coffee

11.10 Panel session: eye of the beholder - how can you achieve European Commission grant success?
Dr Matthias Schroff, Chief Executive Officer, **Mologen**
Christian Rochet, Chief Executive Officer, **Mymetics**
Dr Robert Lambkin-Williams, Chief Executive Officer, **Retroscreen Virology**

11.45 How to source flexible and rapid-response funding for pioneering your vaccine research
Dr Hansi Deans, Director, New Alliances and Initiatives, Research & Development, **IAVI**

SOURCING AND SECURING PRIVATE FUNDING

12.10 What role can corporate venture capital play in furthering your corporate growth?
Deborah Harland, Partner, **SR One Ltd.** (a GSK company)

12.35 How to attract private sector investment, minimise risk and increase confidence in your business
Dr Philippe Pouletty, General Partner, Life Sciences, **Truffle Capital**

13.00 Networking lunch

14.00 How can you successfully engage the private sector and access early stage funding – the biotech perspective?
Dr Philippe Dro, Chief Executive Officer, **GlycoVaxyn**

14.30 Panel session: how can you successfully position your biotech to secure follow-on funding in Europe?
Dr Graziano Seghezzi, Partner, **Sofinnova Partners**
Sten Verland, Partner, **Sunstone Capital**
Dr Magnus Persson, Partner, **HealthCap**

DRIVING AND MAINTAINING FUNDING MOMENTUM

15.10 How to manage the transition from a vulnerable VC dependent state to a more secure target for M&A
Dr Klaus Breiner, Managing Partner, **BB Biotech Ventures**

15.35 How can you keep your funding series moving forward in spite of tightening investment preferences?
Carlton Brown, Chief Executive Officer, **Immune Targeting Systems**

Becoming a sponsor

World Vaccine Congress Lyon 2009 is where your clients will come to look for solutions - solutions you can provide. The *World Vaccine Congress Lyon* will attract the biggest gathering of vaccine businesses to assemble in 2009 in the European region. How are you going to make sure you stand out from the crowd? The simple answer is to invest in the event, invest in your company's future and make sure your client base knows who you are.

Your direct route to market

World Vaccine Congress Lyon is the number one platform for world class vendors and solution providers, to showcase their products and expertise to the biggest ever targeted vaccine audience. This could be your chance to be part of the most cost-effective marketing solution in the vaccine industry. Reduce the time taken to meet new customers, reduce the costs of advertising and maximise the return on your investment.

Who should sponsor and exhibit?

World Vaccine Congress Lyon offers a total marketing and business development solution to companies looking to position themselves at the forefront of the vaccine industry, generate more leads and increase their company's revenue.

- CROs
- CMOs
- EQMs
- Drug delivery
- Clinical trial sites
- Platform providers
- Global consultants
- Biotechs

Delivering real results

No other event can give you exclusive access to senior decision makers from key vaccine, pharmaceutical, biotech companies and government bodies. Sponsoring or exhibiting at *World Vaccine Congress Lyon* is an exceptional opportunity to be part of a 24/7 targeted marketing campaign that not only guarantees a quality audience but also keeps your target markets informed about you.

With one cost-effective investment, *World Vaccine Congress Lyon* will enable you to:

- Start meeting your strategic objectives for the year ahead by putting your company on a platform
- Demonstrate your thought leadership position in the market
- Discuss new product developments
- Conduct real business and build your brand with a group of highly qualified decision-makers
- Develop and reinforce key relationships
- Unrivalled lead generation and profiling
- Target your message to your precise audience

Major industry players have confirmed their early support for 2009. YOU should get organised too!

Contact us TODAY for a tailored sponsorship package to meet your business objectives:

Sylvester Gabriel, Commercial Manager

Tel: +44 (0) 20 7827 5994

Email: sylvester.gabriel@terrapinn.com

"I was extremely satisfied for the level of speakers and the quality of the event: excellent organisation!"

Enric Turmo,
Senior Licensing Manager, Business Development & Licensing, **Esteve**

"Overall it was a great event, I think there is something for all the stakeholders in the vaccine market"

Anil Busimi,
Manager, Business Intelligence,
Schott Schweiz

"Highly stimulating, informative, was able to build contacts to improve business"

Ajit Nair,
Head Business Development, **Vins Bioproducts**

"Very well organized and great networking opportunities"

Visti Wedge,
Business Manager,
NUNC A/S

Sponsors and exhibitors include



Media partners



worldvaccine

CONGRESS 2009

5 - 8 October 2009, Palais de Congrès de Lyon, Lyon, France

World health



Use our online calculator at www.lifescienceworld.com/2009/wvcl

You can use our online calculator to tailor your ticket and buy multiple tickets. The calculator automatically selects the most favourable discount for you. If you book and pay online you also save a further £100.

Register now

Package	Before 17 July 09	Before 28 Aug 09	Before 18 Sept 09	After 19 Sept 09	How many	Calculate your ticket
Platinum pass: 3 day conference PLUS pre-conference regulation day	£3,235 + VAT £634.06 = £3869.06 SAVE £720!	£3,595 + VAT £704.62 = £4299.62 SAVE £360!	£3,775 + VAT £739.9 = £4514.90 SAVE £180!	£3,955 + VAT £775.18 = £4730.18	<input type="checkbox"/>	
Gold pass: 3 day conference	£2,515 + VAT £492.94 = £3007.94 SAVE £560!	£2,795 + VAT £547.82 = £3342.82 SAVE £280!	£2,935 + VAT £575.26 = £3510.26 SAVE £140!	£3,075 + VAT £602.70 = £3677.70	<input type="checkbox"/>	

*Registrations without credit/debit card payments are subject to a £100 booking fee.

How do you want to pay?

Credit / Debit card	<input type="checkbox"/>	£ 0
Cheque / Bank transfer	<input type="checkbox"/>	£ 100
Total		

Biotech Discounts

- ☐ Yes. I am a small / early stage biotech. I therefore qualify for an exclusive discount.
Call Neil Darkes now to find out more details +44 (0)20 7092 1240.

Your voucher code

(you'll need to quote this for telephone and online bookings)

All tickets include refreshments, lunch and full conference documentation. The fee does not include hotel accommodation.

Your details

Delegate name.....

Job title..... Organisation.....

Address.....

Post code..... Country.....

Tel..... Fax.....

Email.....

Authorising manager..... Authorising manager signature.....

Payment details

Payment terms are 14 days from date of invoice. Notwithstanding this, payment must be received prior to the conference taking place. Kindly note the terms and conditions on our registration page.

☐ Bank transfer ☐ Invoice me ☐ Credit card ☐ Diners club ☐ Visa ☐ American express ☐ Mastercard

Card number --- Expiry date: / /

Card holders name..... Card holders signature.....

Bank Transfers: Account Name: Terrapinn Limited, Sort Code: 20-78-98, Bank account number: 30412791, Bank Name & Address: Barclays Bank PLC, 27 Soho Square, London, W1D 3QR, Swift Address: BARCGB22, IBAN: GB14 BARC 2078 9830 4127 91. **Reference: please quote 141575 and the delegate's name**

How to book your ticket

Online

www.lifescienceworld.com/2009/wvcl

You can use our online calculator to tailor your ticket and buy multiple tickets. The calculator automatically selects the most favorable discount for you. If you book and pay online you also save a further \$100.

Offline

You can use our online calculator to tailor your ticket and then print a pdf of your order and fax to +44 (0)20 7242 2320 or complete this form and fax to +44 (0)20 7242 2320 or call +44 (0)20 7242 2324 and we'll take your booking over the phone.

Group bookings

Why not send your team and save more.

Send 3 delegates and save 10%

Send 6 delegates and save 20%

Send 8 delegates and save 25%

To register a group either call +44 (0)20 7242 2324 or fax this form to +44 (0) 207 242 2320.

Privacy policy

Terrapinn may contact you about products and services offered by Terrapinn and its group companies, which Terrapinn believes may be of interest to you, or about relevant products and services offered by reputable third parties. Please tick the appropriate box if you do not wish to receive such information from:

☐ the Terrapinn group; ☐ or reputable third parties.

Cancellation policy

1. Should you be unable to attend, a substitute delegate is welcome at no extra charge.
2. Terrapinn does not provide refunds for cancellations. Invoiced sums are payable in full, except in cases where Terrapinn has been able to mitigate loss.
3. Terrapinn will make available course documentation to a delegate who is unable to attend and who has paid.
4. Terrapinn reserves the right to alter the programme without notice including the substitution, alteration or cancellation of speakers and / or topics and / or the alteration of the dates of the event.
5. Terrapinn is not responsible for any loss or damage as a result of a substitution, alteration, postponement or cancellation of an event.

Don't forget huge discounts are available for group bookings and small biotechs. See above for details.



We lessen this brochure's impact on the environment by using recycled paper.